Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases. Cambridge Brain Mets Trial 1 (CamBMT1): A proof of principle study of ...
Despite global vaccination efforts, COVID-19 continues to pose significant risks, leading to severe complications and fatalities. These risks are driven by disrupted coagulation, impaired fibrinolysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results